Matrix metalloproteinase-9 measured in urine from bladder cancer patients is an independent prognostic marker of poor survival

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Department of Experimental Clinical Oncology
  • The Department of Oncology
Matrix metalloproteinase 9 (MMP-9) is an endopeptidase involved in various cellular processes, such as tumour development and metastatic spread. In biological samples, MMP-9 can occur as pro-MMP-9 and active MMP-9, or these factors complexed with the inhibitor TIMP-1. An assay, which can measure active and total MMP-9 in biological samples, has been used on the urine from bladder cancer patients and demonstrated a significant correlation between MMP-9 and clinical parameters. The prognostic value of these measurements has never been investigated. Using this assay we have investigated the prognostic influence of total and active MMP-9 in urine from bladder cancer patients.
Original languageEnglish
JournalActa Oncologica
Pages (from-to)1283-7
Number of pages5
Publication statusPublished - 1 Nov 2010

    Research areas

  • Adult, Aged, Aged, 80 and over, Creatinine, Female, Humans, Kaplan-Meier Estimate, Male, Matrix Metalloproteinase 9, Middle Aged, Neoplasm Staging, Predictive Value of Tests, Prognosis, Proportional Hazards Models, Risk Assessment, Risk Factors, Survival Analysis, Tissue Inhibitor of Metalloproteinase-1, Tumor Markers, Biological, Urinary Bladder Neoplasms

See relations at Aarhus University Citationformats

ID: 34409952